Using Mirabegron to Control Arrhythmia-1

NCT07566208 | Not Yet Recruiting Phase 2 FDA Drug

• 1 other identifier: STUDY00004239
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

To evaluate mirabegron's effect on ventricular arrhythmia control. The study will be conducted in ambulatory patients with ventricular tachycardia (VT), organic heart diseases, and an implantable cardioverter-defibrillator (ICD). The investigators will perform a pilot study involving 20 patients. Each will receive 50 mg of mirabegron. All will have neuECG recordings made before and 2 months after mirabegron. The data will be analyzed to test the proposed hypothesis.

Conditions

Ventricular Arrhythmias and Cardiac Arrest

Keywords

mirabegron; Ventricular tachycardia; Ventricular fibrillation; ICD

Outcome Measures

Primary Outcomes (1)

• The primary endpoint is reduction of the burden of VT detected by ICD

  The patients with ICD will record the VT burden. The investigators will use that number as the primary outcomes measure.

  3 months

Study Arms (1)

mirabegron

EXPERIMENTAL

The investigators will give the patients 50 mg/day of mirabegron orally for three months.

Drug: Mirabegron

Interventions

Mirabegron DRUG

Mirabegron is a beta-3 agonist approved by FDA to treat overactive bladder. Our preclinical studies showed that it is antiarrhythmic in the ventricles.

mirabegron

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• In order to be eligible to participate in this study, an individual must meet all the following criteria:
• Provision of signed and dated informed consent form.
• Age \> 18 years old.
• Documented VT on ICD.
• with \> 2 episodes of VT per month (on average) over the past 2 months.
• despite guideline-recommended medical therapy (GRMT).

You may not qualify if:

• An individual who meets any of the following criteria will be excluded from participation in this study:
• Patients who are pacemaker-dependent because the pacing artifacts will complicate skin sympathetic nerve activity (SKNA) analysis.
• Clinically unstable (for example, acute myocardial infarction, decompensated heart failure, undergoing cancer chemotherapy, and other acute illness requiring hospitalization)
• Uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both)25
• Active thyrotoxicosis
• Any experimental medication concomitantly or within 4 weeks of participation in the study
• Currently participating in a different clinical trial
• Severe renal impairment (CrCl \< 30 ml/min)
• Hepatic disease (Child-Pugh Class C)
• Pregnant
• Breastfeeding
• Cannot speak, write, and answer questions in English
• Does not have the capacity to consent
• Severe renal impairment (CrCl \< 30 ml/min)
• Hepatic disease (Child-Pugh Class C)

Sponsors & Collaborators

• Cedars-Sinai Medical Center: lead

MeSH Terms

Conditions

Heart Arrest; Tachycardia, Ventricular; Ventricular Fibrillation

Interventions

mirabegron

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Tachycardia; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Peng-Sheng Chen, MD

CONTACT

310-967-2707; peng-sheng.chen@csmc.edu

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Staff Physician III

Study Record Dates

• First Submitted: April 29, 2026
• First Posted: May 5, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): May 1, 2028
• Study Completion (Estimated): May 1, 2028
• Last Updated: May 6, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share